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ABSTRACT 
Activation of mitochondrial ATP-sensitive potassium (KATP) channels is postulated as 
an effective mechanism to confer cardio and neuroprotection, especially in situations 
associated to oxidative stress. Pharmacological activation of these channels inhibits 
glia-mediated neuroinflammation. In this way, diazoxide, an old-known mitochondrial 
KATP channel opener, has been proposed as an effective and safe treatment for different 
neurodegenerative diseases, demonstrating efficacy in different animal models, 
including the experimental autoimmune encephalomyelitis (EAE), an animal model for 
Multiple Sclerosis. Although neuroprotection and modulation of glial reactivity could 
alone explain the positive effects of diazoxide administration in EAE mice, little is 
known of its effects on the immune system and the autoimmune reaction that triggers 
the EAE pathology. The aim of the present work was to study the effects of diazoxide in 
autoimmune key processes related with EAE, such as antigen presentation and 
lymphocyte activation and proliferation. Results show that, although diazoxide 
treatment inhibited in vitro and ex-vivo lymphocyte proliferation from whole 
splenocytes it had no effect in isolated CD4
+
 T cells. In any case, treatment had no 
impact in lymphocyte activation. Diazoxide can also slightly decrease CD83, CD80, 
CD86 and major histocompatibility complex class II expression in cultured dendritic 
cells, demonstrating a possible role in modulating antigen presentation. Taken together, 
our results indicate that diazoxide treatment attenuates autoimmune encephalomyelitis 
pathology without immunosuppressive effect. 
Key Words: Diazoxide; KATP channels; EAE mice; spleen; lymphocyte; dendritic cell. 
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INTRODUCTION 
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS). It is hypothesized that the disease is caused by an autoimmune 
reaction orchestrated by myelin-specific CD4
+ 
Th1 that results in demyelination and 
neuronal injury (Trapp and Nave 2008). T cells are key players in shaping the immune 
responses by directly secreting soluble mediators or through cell contact-dependent 
mechanism (Goverman 2009). In experimental autoimmune encephalomyelitis (EAE), 
the classical animal model for MS, Th1 cells have been shown to promote inflammation 
within the CNS and facilitate Th17 cell infiltration into the CNS (O'Connor and 
Anderton 2008). In this context, it has been suggested that encephalitogenic T cells that 
invade the CNS during disease interact locally with antigen presenting cells (APCs), 
resulting in both, re-activation of the T cells and activation of the APCs (Shrikant and 
Benveniste 1996). Different cell types including resident astrocytes and microglia as 
well as infiltrating macrophages and dendritic cells (DC)  are potential APCs inside the 
CNS (Carson et al. 2006).  While APCs constitutively express CD45, CD86 and CD40 
at low levels (Carson et al. 1998), expression of CD45, major histocompatibility 
complex class II (MHC class II), CD80, CD86 and CD40 appear to be upregulated in 
response to inflammatory stimuli, thus enhancing their ability to function as APCs 
(Shrikant and Benveniste 1996).  
Potassium channels play an important role in the cardiovascular system and in the CNS. 
They are critically involved in regulating signaling, proliferation, secretion and 
migration not only in neurons but also in glial cells such as astrocytes and microglia 
(Olsen and Sontheimer 2008; Skaper 2011; Steinhauser et al. 2012; Rodriguez et al. 
2013). Potassium channels have been also described to modulate the immune response. 
For instance, the relevance of the voltage-gated K
+ 
channel Kv1.3 (Beeton et al. 2006; 
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Judge and Bever, Jr. 2006) and the Ca
2+
-dependent K
+
 channel KCa3.1 (Ghanshani et 
al. 2000) in the immune system has been widely documented. Recently, the TWIK-
related acid sensitive potassium channel 2 (K2P5.1, KCNK5, TASK2) has been 
postulated as new K
+
 channel that is a critical player in T-cell effector function (Meuth 
et al. 2008; Bittner et al. 2010).  
ATP-sensitive K
+
 (KATP) channels are large hetero-octameric complexes consisting of 
four pore-forming inward-rectifying K
+
 subunits (Kir6.x) and four regulatory 
sulfonylurea receptor (SURx) subunits (Mannhold 2004). They are considered 
metabolic sensors that couple cellular energy metabolism to membrane excitability by 
regulating potassium flux. These channels act as energy sensors of ATP production and 
are believed to regulate various physiological functions, such as muscle contraction and 
insulin secretion, by coupling cell metabolism to membrane potential (Nichols 2006). 
KATP channels are also present at the mitochondrial inner membrane (mito-KATP) where 
they participate in the regulation of mitochondrial volume and membrane potential 
(m). Furthermore, their activity is related to electronic transport, metabolic energy, 
reactive oxygen species (ROS) production and mitochondrial welfare (Busija et al. 
2008; Xie et al. 2010). Diazoxide (7-chloro-3-methyl-4H-1,2,4-benzothiadiazine 1,1-
dioxide) is a well-known small molecule that opens KATP channels with high affinity for 
mito-KATP channels. Our previous studies demonstrated that oral administration of 
diazoxide ameliorated disease progression in EAE and caused neuroprotection (Virgili 
et al. 2011; Virgili et al. 2013). Diazoxide elicited a significant reduction in myelin and 
axonal loss accompanied by a decrease in glial activation and neuronal damage without 
affecting the number of infiltrating lymphocytes positive for CD3 and CD20 in the 
spinal cord (Virgili et al. 2011). These results demonstrated novel actions of diazoxide 
as glial mediated anti-inflammatory and neuroprotective agent, although the effects of 
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KATP channel openers (KCOs) in the immune system are poorly understood. It has been 
described that diazoxide suppresses leukemic cell proliferation through depolarization 
of the mitochondrial membrane and disruption of intracellular Ca
2+
 dynamics 
(Holmuhamedov et al. 2002). Other studies demonstrated a reduction of leukocyte 
adhesion and migration by KCOs (nicorandil and diazoxide) in tissue subjected to 
ischemia/reperfusion (Yasu et al. 2002). Recently, it has been showed that activation of 
mito-KATP channels reduced apoptosis on spleen mononuclear cells induced by 
hyperlipidemia (Alberici et al. 2013). Here, we have addressed the possible peripheral 
actions of diazoxide modulating specific or non-specific lymphocyte activation. Thus, 
our aims were: A) To analyze the effect of diazoxide on proliferative response in the 
EAE model, and B) To analyze the KATP channel expression in CD4
+
 T cells and to 
study proliferative lymphocyte response in specific anti-CD3-CD28 activation 
lymphocyte model. 
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MATERIAL & METHODS 
Mice 
Female C57BL/6J mice, 8 to 10 weeks of age, were purchased from Janvier (Le Genest-
Saint-Isle, France) and maintained on a 12:12 hours light:dark cycle, with standard 
chow and water freely available. Females were used due to their better incidence and 
clinical course of the disease and also for the recommendation to use females in animal 
models for Multiple Sclerosis, a disease with higher incidence in females than males 
(Rahn et al. 2014). Animal were handled according to European legislation (86/609/EU) 
and procedures were approved by the Ethics and Scientific Committees of the 
University of Barcelona (UB) and registered at the “Departament d'Agricultura, 
Ramaderia i Pesca, Generalitat de Catalunya, Spain”. All animals used for treatment 
comparisons were subject to the same conditions, individuals distributed randomly to 
treatment or control groups and experimental procedures were performed at the same 
time in order to guarantee maximal homogeneity and avoid the influence of individual 
factors such estrous cycling that could interfere with data analysis (Rahn et al. 2014). 
 
Reagents 
Diazoxide was purchased from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions 
(50 mM) of diazoxide were prepared in dimethyl sulfoxide (DMSO, Sigma-Aldrich). 
Solutions for cell treatment were prepared by diluting the stock solution in culture 
media immediately before being added to the cells (final DMSO concentration: 0.5%). 
Solutions for animal treatment were prepared by diluting the stock solution at each 
treatment day (final DMSO concentration: 0.3%).  
 
Mouse splenocytes and CD4
+
 T cells preparation  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
 
Splenocytes were isolated from the spleens of mice. Cells were gently flushed out from 
the spleens using a syringe plunger with PBS and then centrifuged (1000rpm, 4ºC). The 
pellet was resuspended and left 5 minutes on ice in ACK lysing buffer (Invitrogen, 
Eugene, OR, USA) to remove erythrocytes. After further centrifugations, cells were 
resuspended in 10 ml of complete medium RPMI (Invitrogen) supplemented with 10% 
Fetal Bovine Serum (FBS, Invitrogen), Hepes 10mM (Invitrogen), Sodium Pyruvate 
1mM (Invitrogen), non-essential aminoacids 1% (Sigma-Aldrich) and 50M -
Mercaptoetanol (Sigma-Aldrich).  
CD4
+
 T cells were isolated using Dynabeads FlowComp Mouse CD4
+
 kit (DYNAL, 
Invitrogen) following manufacturer’s instructions. After isolation, cells were counted 
and the viability was determined by trypan blue exclusion. The purity for CD4
+
 cells 
(>92%) was assessed by FACS (Gallios BD Bioscience).  
 
EAE induction and treatment 
EAE was induced by immunization with > 95% pure synthetic myelin oligodendrocyte 
glycoprotein peptide 35-55 (rat MOG 35-55, MEVGWYRSPFSRVVHLYRNGK; 
EspiKem Srl, Florence, Italy). Mice were injected subcutaneously at one side of the 
flank with 100 μL solution containing 150 µg of rat MOG in complete Freund’s 
adjuvant (Sigma-Aldrich) and 5 mg/mL Mycobacterium tuberculosis H37Ra (Difco 
Laboratories, Detroit, MI, USA). Mice also received intraperitoneal injections of 150 ng 
pertussis toxin (Sigma-Aldrich) in 100 µL PBS immediately after MOG injection and 
48 hours later. Mice were scored daily for signs of EAE on a scale of 0 to 6 using the 
following criteria: 0, no clinical signs; 1, distal limp tail; 1.5, complete limp tail; 2, mild 
paraparesis of the hind limbs, unsteady gait and impairment of righting reflex; 3, 
moderate paraparesis, partial hind limb paralysis, voluntary movements still possible 
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and ataxia; 4, paraplegia and forelimb weakness; 5, tetraparesis; 6, moribund state. 
When clinical signs were intermediate between two grades of the disease, 0.5 was added 
to the lower score. Treatment began when the EAE clinical score was ≥ 1 (appearance 
of clinical signs). The MOG-immunized mice were administered either 0.8 mg/kg 
diazoxide (treated group) or diluent (0.3% DMSO in water, vehicle group) for 15 days 
by oral gavage.  
 
Proliferative response of lymphocytes and treatment 
Splenocytes were isolated from the spleens of EAE mice after 15 days of diazoxide or 
vehicle treatment (n=3 per each group) and assayed ex vivo for their response to specific 
lymphocyte stimulus anti-CD3 (KT3, coated at 1g/ml; Serotec, Oxford, England, UK) 
and anti-CD28 (37.51, coated at 2.5 g/ml; eBioscience, San Diego, CA, USA). For in 
vitro studies, splenocytes and CD4
+
 T cells were isolated from wild type animals.  
Proliferation assay was carried out by plating 2.10
5
cells/well in 96 well plates and 
exposed to anti-CD3/CD28 for 72 hours. Cells were treated with diazoxide at various 
concentrations (100-0.1 M) after plating and the treatment remained during 72 hours. 
Cell proliferation was determined by colorimetric Bromodeoxyuridine (BrdU) Cell 
Proliferation kit (Calbiochem, Darmstadt, Germany) following manufacturer's 
instructions. In brief, 20 l of BrdU labelling solution diluted 1:2000 in a culture 
medium was added to each well for the last 18h of culture. After removing the medium, 
cells were fixed, and the anti-BrdU peroxidase working solution was added to each well 
and incubated for an hour at room temperature. Following several washes, the substrate 
solution was added, color was developed, and absorbance was measured with a 
microplate reader at 450 nm. Proliferation rate was calculated as follows: the 
absorbance of cells in the presence of anti-CD3-CD28 divided by the absorbance of 
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cells in the absence of antibodies. Moreover, carboxyfluorescein succinimidyl ester 
(CFSE, Invitrogen) (2.5 M) staining was used to confirm proliferation of the CD4-
positive population in the whole splenocytes culture. 
 
Generation, maturation and treatment of mouse bone-marrow derived dendritic 
cells (BMDCs) 
Bone marrow from C57BL/6 mice was harvested by flushing femurs. After a washing 
and a centrifugation step cells were diluted in Petri dish to final concentration of 4.10
6 
cell/ml. Bone marrow progenitor cells were cultured in the presence of 
granulocyte/macrophage colony-stimulating factor (GM-CSF) to stimulate proliferation 
and maturation of DCs. Cells were maintained at 37ºC and 5%CO2. Media and GM-
CSF was replaced at day 3, 6 and 8 after. At day 9, lipopolysaccharide (LPS, 1 g/ml, 
Sigma) was added for 24 hours to induce DC maturation. To explore if the compound 
has an effect on DC development, cells were treated from the first day of DC isolation 
with different concentrations of diazoxide (100-0.1 M). Moreover, to discriminate if 
the compound acts on DC development or on DC maturation, on day 9, one diazoxide 
group was treated with LPS while the other remained unstimulated. On day 10, after 24 
hours LPS treatment, DCs were harvest and stained for phenotype and maturation 
markers for flow cytometry.  
 
Flow cytometry  
Cells were resuspended in FACS buffer and blocked with anti-mouse CD16/32 
(eBioscience) for 15 minutes and, then, stained with different combinations of primary -
conjugated Abs for 20 minutes at 4ºC. After a washing step, cells were resuspended in 
FACS buffer and analyzed by FACS (FACSGallios, BD Biosciences, San Jose, CA, 
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USA). The following antibodies were used: For spleen lymphocytes determination, 
CD4-PE  (dil. 1:200) (eBiosciense). For lymphocytes activation studies CD69-FITC, 
CD25-APC, CD4-PE or -APC (dil. 1:200) (eBioscience). For surface DC staining, 
CD83-APC, MHCII-FITC, CD80-PerCP-Cy5.5 and CD86-APC-Cy7 (dil. 1:200) (BD 
Bioscience). 7-AAD  was used to determinate the living population (eBioscience).  
 
Isolation of total protein 
For isolation of total proteins from cell cultures, after a cold PBS wash, total proteins 
were recovered in 80 μL per well of RIPA buffer supplemented with complete protease 
inhibitor cocktail tablets. The samples were sonicated and stored at −80°C. Protein 
amount was determined by the Lowry assay (Total Protein Kit micro-Lowry, Sigma-
Aldrich). 
 
Western blot 
40 μg of proteins from denatured (100°C for 5 minutes) total extracts were subjected to 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis together with a molecular 
weight marker (Full Range Rainbow Molecular Weight Marker, Amersham, 
Buckinghamshire, UK), and transferred to a polyvinylidene difluoride membrane 
(Millipore, Bedford, MA, USA). After washing in Tris-buffered saline (TBS: 20 mM 
Tris, 0.15 M NaCl, pH 7.5) for 5 minutes, dipping in methanol for 10 s and drying in 
air, the membranes were incubated with the following primary antibodies overnight at 
4°C: polyclonal rabbit anti-Kir6.1 or polyclonal rabbit anti-Kir6.2 (both 1:200, 
Alomone, Jerusalem, Israel), polyclonal rabbit anti-SUR1 (1:100, Alomone) and 
monoclonal mouse anti-β-actin (1:100000, Sigma-Aldrich) diluted in immunoblot 
buffer (TBS containing 0.05% Tween-20 and 5% non-fat dry milk). The membranes 
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were then washed twice in 0.05% Tween-20 in TBS for 15 s and incubated with the 
following horseradish peroxidase (HRP)-labeled secondary antibodies for 1 hour at 23 
to 25°C: donkey anti-rabbit (1:5000, Amersham) or goat anti-mouse (1:5000, Santa 
Cruz Biotechnology, St. Cruz, CA, USA).  After extensive washes in 0.05% Tween-20 
in TBS, they were incubated in ECL-Plus (Amersham) for 5 minutes. Membranes were 
then exposed to the camera and the pixel intensities of the immunoreactive bands were 
quantified using the percentage adjusted volume feature of Quantity One 5.6.4 software 
(Bio-Rad Laboratories, Hercules, CA, USA).  
 
Histological and immunohistochemical analysis 
Hematoxylin and eosin (H&E) staining was used for the histological spleen studies. For 
immunohistochemical studies and cell staining, EAE spinal cord sections and CD4
+
 T 
cells were first blocked in PBS (0.5% Triton) containing 10% goat serum (Vector) for 
2h. Sections were then incubated with anti-CD3 (1:300, Serotec) and anti-Kir6.2 (1:300, 
Alomone, Jerusalem, Israel) at 4ºC overnight, followed by secondary antibodies Alexa 
488 and 596 (1:2000 and 1:500, respectively) for 2h. Nuclear stain Hoechst 34580 (2 
g/mL; Invitrogen) was added prior to final washes and then samples were mounted 
using ProLong Gold antifade medium (Invitrogen). 
 
Statistical Analysis 
Data are expressed as the mean ± SEM unless specified. Statistical analysis of cell 
treatments was carried out using one-way ANOVA followed by Newman-Keuls post 
test when three or more experimental groups were compared and t-student for two 
groups comparison. Data on the effect of EAE treatment on clinical signs were analyzed 
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using the Mann–Whitney test for nonparametric data. Values of p<0.05 were considered 
statistically significant. 
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RESULTS 
Lymphocyte proliferation is decreased in spleens from diazoxide treated EAE mice 
EAE mice were orally treated with 0.8 mg/kg diazoxide from the onset of clinical signs 
(clinical score > 1) of the disease for a period of 15 days. Diazoxide treatment showed a 
beneficial effect on the disease severity compared to vehicle treated animals (Figure 
1A). The amelioration was significant in the initial and in the chronic phase of the EAE 
(At day 3, 4 and 15, p < 0.05). No adverse effects related to the treatment were observed 
in any of the treated animals. At the end of the treatment, spleens from EAE animals 
were dissected and splenocytes isolated after erythrocyte lysis. Afterward, flow 
cytometry for CD4 positive cells were performed in isolated splenocytes. Results 
showed that diazoxide did not alter the percentage of CD4 positive events (32.1±1.6 
from EAE vehicle vs. 31.1±1.7 from EAE diazoxide, t = 0.4, p  > 0.05, t-test) (Figure 
1B). In addition, we examined the proliferative capacity of splenocytes under unspecific 
T lymphocyte stimulation with anti-CD3 and anti-CD28 antibodies. After 72 hours of 
stimulation, proliferation was reduced in cells obtained from diazoxide treated animals 
when compared to vehicle treated EAE mice (4.6 ± 0.6 vs. 6.7 ± 0.9 respectively; t = 
1.89, p = 0.035, t-test) (Figure 1C). Moreover, spleens from vehicle and diazoxide 
treated EAE mice displayed different morphology. Whereas in control EAE mice 
spleens showed reduced size and external signs of necrosis, in diazoxide treated animals 
spleens were better preserved and resembled in size and aspect those from non-
immunized animals (Figure 2A). Upon cellular count, results showed an increase of 
mononuclear cells in diazoxide treated animals compared to vehicle group (EAE 
diazoxide: 45.10
6  
± 5.10
6
; EAE vehicle 27.10
6  
± 4.10
6 
cells, t = 2.9,  p = 0.0067, t-test) 
(Figure 2B). H&E staining of histological sections from EAE spleens confirmed the 
preservation of spleen histoarchitecture in diazoxide treated animals (Figure 2C). In 
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contrast, spleens from vehicle EAE mice showed clear signs of atrophy, condensed 
nuclei and intercellular disruption (insert in Figure 2C). 
 
SUR and Kir KATP channels subunits are expressed in splenocytes, CD4
+
 isolated 
cells and CD3 infiltrated lymphocytes. 
In order to elucidate if KATP channels subunits are expressed in lymphocytes, 
immunofluorescence detection for Kir6.2 and CD3 was performed in both, CD4
+
 spleen 
isolated cells and CD3 infiltrated lymphocytes in the spinal cord from EAE animals. 
Upon microscopic observation, results showed positive expression of CD3 and Kir6.2 in 
most of CD4
+
 T cells (Figure 3A). Spinal cord infiltrated T lymphocytes identified as 
CD3 positive cells also showed Kir6.2 expression (Figure 3B). Kir6.1, Kir6.2 and SUR1 
expression was also analyzed in total splenocytes and CD4 positive T cells isolated 
from spleen by western blotting. Results showed positive signaling for all the KATP 
channel subunits studied in both, splenocytes and isolated CD4
+
 cells (Figure 3C).  
 
Diazoxide does not influence lymphocyte activation 
In order to explore if diazoxide could modulate the activation of lymphocytes, we 
analyzed an early activation surface marker, CD69, and a late activation surface marker, 
CD25 on splenocytes and CD4
+
 cells by flow cytometry. Generally, mouse T cells in 
vitro show a relatively low activation status. Anti-CD3-CD28 stimulation after 4h 
showed a high increase of CD69 expression in T cell population by close to tenfold. 
Diazoxide treatment did not modulate the percentage of positive CD69 cells at any dose 
tested in splenocytes cells (100 and 0.1 M, F(2,8  ) = 1.2,  p > 0.05) (Figure 4A). Similar 
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results were observed for the CD25 marker. As shown in the representative flow 
cytometry diagrams, the anti-CD3-CD28 stimulation after 16h increased CD25 
expression by close to tenfold. This activation was not modified by diazoxide treatment 
(100 and 0.1 M, F(2,8) = 4.1, p > 0.05) (Figure 4B). The same results were observed 
when experiments were performed in CD4
+
 isolated population for CD69 (F(2,11  ) = 0.4, 
p > 0.05) and CD25 (F(2,11) = 0.2, p > 0.05) activation T-cell markers (Figure 4 A-B). 
Taken together, results showed that diazoxide does not influence the activation rate of 
lymphocytes.  
 
Diazoxide modulates proliferation of splenocytes but not of isolated CD4
+
 T cells  
In order to clarify if diazoxide has a direct effect on lymphocytes proliferation, an ex 
vivo BrdU incorporation proliferation assays were performed on splenocytes from 
healthy spleen mice. Lymphocyte proliferation was induced by direct T cell receptor 
(TCR) engagement using anti-CD3-CD28 stimulation. Stimulated splenocytes showed a 
5 fold increased proliferation compared to unstimulated cells (Figure 5A). Our results 
showed a diazoxide-related decrease in proliferation rate compared to CD3-CD28 
stimulated splenocytes (up to 45 ± 7% for 100 M and 37 ± 9% for 0.1 M, F(4,19) = 8.0, 
p = 0.0021) (Figure 5A). CFSE labeling was used to confirm these results and to prove 
that proliferating cells were indeed CD4-positive T cells (data not shown). To explore if 
this decrease in proliferation was a direct effect on the CD4
+
 T cell population, the same 
proliferation experiments were performed using sorted CD4
+
 T cells. Stimulated CD4
+
 
T cells showed a 5.8 fold increased proliferation compared to unstimulated cells (Figure 
5B). However, when CD4
+
 T cells were treated with different concentrations of 
diazoxide, the effect was abolished and no significant changes in proliferation rate were 
observed (F(4,19) = 1.7, p > 0.05) (Figure 5B). No change of viability was observed by 
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flow cytometry using PI (data not shown). These results indicate that diazoxide does not 
have a direct effect on isolated lymphocytes but could modulate immune intercellular 
communication affecting splenocyte proliferation. 
 
Diazoxide modulates dendritic cell development and maturation 
The results presented above indicate that diazoxide may modulate T cell response by 
influencing accessory cells such as antigen-presenting cells (APCs). Dendritic cells 
(DCs) are professional APCs that play a key role in initiating and regulating the 
immune response. To explore the effect of diazoxide on DCs differentiation and antigen 
presenting capacity, DCs were generated in vitro from mouse bone marrow progenitor 
cells in the presence of GM-CSF. To explore if diazoxide has an effect on DCs 
development, cells were treated from the first day of isolation with different 
concentrations of compound (100 - 0.1 M). Moreover, to discriminate if the compound 
acts on DC development or on DC maturation, one of the DC cultures was treated on 
day 9 with 1g/ml LPS for 24 hours, while the other remained unstimulated. 
Afterwards, the percentage of DCs positive for CD83, used as marker for DC 
development, was analyzed. Results showed a percentage decrease of CD83 in DCs 
treated with diazoxide compared to DCs control. This decrease was mainly observed at 
low diazoxide doses in both LPS stimulated DCs (0.1 M: 13 ± 1%, F(3,11) = 12.4, p = 
0.0055) and unstimulated DCs (0.1 M: 33 ± 7%, F(3,11) = 5.4, p = 0.0382) (Figure 6 A-
B). 
Next, the expression on DCs of the co-stimulatory markers CD80, CD86 as well as the 
expression of MHCII were analyzed by flow cytometry. Results showed that, the 
percentage of positive events for the markers was slight decreased in diazoxide treated 
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DCs when compared with the control DCs. This decrease was significant for CD80 at 
0.1 and 10 M diazoxide (F(4,34) = 4.1, p = 0.0107) but not for CD86 (F(4,34 ) = 1.4, p > 
0.05) and MHCII (F(4,29) = 0.7, p > 0.05) (Figure 6 C). Moreover, the amount of 
molecules expressed on a single cell as reflected by mean fluorescence intensity (gMFI) 
was slight decreased by the treatment (data not shown). These results indicate that 
diazoxide, particularly at low doses, can attenuate DC development and antigen 
presenting capacity. 
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DISCUSSION 
KATP channel activators such as diazoxide are well known compounds with approved 
use for the treatment of hypoglycemia and hypertension and with well documented 
cardio and neuroprotective properties (Miura and Miki 2003; Yamada and Inagaki 
2005; Judge and Smith 2009). However, little is known about their effects on the 
immune system. Therefore, the present work focused on the immune effects of 
diazoxide during MOG35-55-induced EAE. Our results demonstrate that diazoxide, at 
tested doses, promoted a significant improvement of the clinical course of the EAE, 
without suppressing lymphocyte activation and CNS infiltration. Nevertheless, spleens 
from treated animals showed a better preservation and lower proliferative capacity 
under lymphocytic stimulation ex vivo, indicating a general reduced T cell 
responsiveness in the treated animals. In addition, our results demonstrated for the first 
time the expression of Kir6.1, Kir6.2 and SUR1 of KATP channel subunits in CD4
+
 
lymphocytes. However, in vitro addition of diazoxide inhibited T cell proliferation but 
only when total splenocytes were used and not when isolated CD4
+
 cells were treated. 
Yet, in the in vitro cultures using whole splenocytes, the proliferating lymphocytes were 
identified as CD4
+
 by flow cytometry. Diazoxide shows no effects in lymphocyte 
activation but can succinctly affect DC differentiation and their expression of CD80 
molecules. Even though the observed changes were modest, the effect was constant and 
significant. As the anti-CD3-CD28 stimulation is independent of antigen presentation, 
the decreased T cell proliferation observed in splenocytes could be caused by diazoxide-
induced factors in cells other than CD4
+
 T cells. This effect could be for instance 
attributed to IL-10, which may enhance regulatory T cell response and, thereby, 
downregulate CD4
+
 proliferation after antigenic stimulus (Marshall et al. 2003). 
However, further analysis of soluble factors is required to explain the acute anti-
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proliferative effect of diazoxide as long as,  although the activation may have not been 
affected, the differentiation may have been altered. Additional analysis on the MOG-
specific CD4
+
 T cells ex vivo would be also interesting. 
T cell imprinting and lymphocyte activation by antigen presentation is the key step for 
inducing an effective adaptive (auto) immune response (Mora et al. 2005; Abadie et al. 
2009). Besides other factors, calcium signaling, modulated by mitochondrial activity 
and bioenergetic metabolism can modify both, the antigen presenting cell behavior and 
lymphocyte activation (Carrasco-Marin et al. 1998; Quintana et al. 2009). In this 
context,  potassium channels such as Kv1.3 or KCa3.1 has been postulated as possible 
targets for the treatment of autoimmune disorders (Toldi et al. 2011; Gocke et al. 2012; 
Kuras et al. 2012; Wang et al. 2013).  KATP channels could regulate extracellular 
calcium signaling linking cell metabolism with membrane electric potential and, thus, 
emerging as an interesting target for immune modulation. Diazoxide has been described 
to suppress Jurkat proliferative rate through mitochondrial targeting by inhibiting influx 
Ca
2+
 release-activated Ca
2+
 channels (ICRAC) dependent calcium mobilization 
(Holmuhamedov et al. 2002). These results, although they are difficult to extrapolate to 
physiological lymphocyte activity, demonstrate the capacity of KCOs to modulate 
lymphocytic behavior. KATP channel activators have been proposed to modulate 
inflammatory activity in different situations: diazoxide has been described to favorably 
shift the systemic cytokine balance after coronary artery bypass towards an anti-
inflammatory response increasing the ratio of IL-10 in relation to pro-inflammatory 
cytokines (Wang et al. 2004). Moreover, nicorandil and diazoxide were shown to 
regulate leukocyte activation by inhibiting polymorphonuclear leukocyte migration 
upon ischemia reperfusion (Yasu et al. 2002). Interestingly, regarding the local CNS 
inflammatory activity, various authors showed that diazoxide exerts an anti-
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inflammatory effect in microglia (Zhou et al. 2008; Virgili et al. 2011), the resident 
macrophage of the CNS and one of the main immune effectors during EAE (Almolda et 
al. 2011). Our results now suggest that, although diazoxide could not suppress 
lymphocyte activation it could attenuate autoimmune damage by modulating innate 
immune response, splenocytes proliferation rate and antigen presentation. These results 
agree with the previous reported effects of oral diazoxide administration in EAE 
animals, where preventive administration of the compound did not suppress the 
generation of autoimmunity or lymphocyte infiltration but reduce the area affected by 
the inflammatory autoimmune attack (Virgili et al. 2011).  The effects of diazoxide as 
immunomodulator could be related to its protective capacities against cellular stress 
(Ichinose et al. 2003; Huang et al. 2006; Liu et al. 2006). For instance, spleens from 
EAE treated mice showed high level of preservation probably as a consequence of a 
reduced oxidative stress. In this context, a recent study demonstrated that activation of 
the mito-KATP channel reduced apoptosis of spleen mononuclear cells induced by 
hyperlipidemia (Alberici et al. 2013). During immune activation, it is well known that 
cellular stress and apoptosis could generate a positive feedback loop that would increase 
inflammatory damage (Freund et al. 2010; Gallo and Gallucci 2013). Moreover, atrophy 
of the thymus, spleen and lymph nodes has been demonstrated to be associated to an 
increased Th1 versus Th2 response and an enhanced MOG antibody production in EAE 
mice (Tsunoda et al. 2005). In this context, apoptosis inhibition, mitochondrial 
stabilization and anti-oxidative mechanisms, which are well-described actions of 
diazoxide (Ichinose et al. 2003; Liu et al. 2006; Moghtadaei et al. 2012), may contribute 
to control the autoimmune reaction also in the absence of immunosuppression.  
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
 
ACKNOWLEDGEMENTS 
We thank Dr. Pablo Villoslada and the members of the Neuroimmunology Group from 
Hospital Clínic-IDIBAPS, Barcelona, Spain for their scientific and technical assistance. 
We also thank Dr. Javier Bustos from Neurotec Pharma and Dr. Georgina Sorrosal, Dr. 
Clara Campàs, Dr. Mercè de Frias from Advancell for their critical review of the 
manuscript. MJR work is supported by grantIPT-2012-0614-010000 from the 
Ministerio de Economia, and by grant 2009SGR1380 from the Generalitat de 
Catalunya, Spain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
22 
 
COMPETING INTERESTS 
NV, PM, MP, JFEP have applied for a PCT application ‘‘Diazoxide for use in the 
treatment of a central nervous system (CNS) autoimmune demyelinating disease’’ 
(application number PCT/EP2011/050049). MP is CEO in Neurotec Pharma and also 
holds shares in the company. NV, PM, BW, JFEP are employed in Neurotec Pharma. 
CC, AW, MJR and CID declares no competing interests. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
23 
 
REFERENCES 
Abadie, V., Bonduelle, O., Duffy, D., Parizot, C., Verrier, B., & Combadiere, B. (2009) 
Original encounter with antigen determines antigen-presenting cell imprinting of the 
quality of the immune response in mice. PLoS.One. 4: e8159. 
Alberici, L. C., Paim, B. A., Zecchin, K. G., Mirandola, S. R., Pestana, C. R., Castilho, 
R. F., Vercesi, A. E., & Oliveira, H. C. (2013) Activation of the mitochondrial ATP-
sensitive K+ channel reduces apoptosis of spleen mononuclear cells induced by 
hyperlipidemia. Lipids Health Dis. 12: 87. 
Almolda, B., Gonzalez, B., & Castellano, B. (2011) Antigen presentation in EAE: role 
of microglia, macrophages and dendritic cells. Front Biosci. 16: 1157-1171. 
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., 
Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., Wang, P. H., LeeHealey, C. J., 
Andrews, S., Sankaranarayanan, A., Homerick, D., Roeck, W. W., Tehranzadeh, J., 
Stanhope, K. L., Zimin, P., Havel, P. J., Griffey, S., Knaus, H. G., Nepom, G. T., 
Gutman, G. A., Calabresi, P. A., & Chandy, K. G. (2006) Kv1.3 channels are a 
therapeutic target for T cell-mediated autoimmune diseases. Proc.Natl.Acad.Sci.U.S.A 
103: 17414-17419. 
Bittner, S., Bobak, N., Herrmann, A. M., Gobel, K., Meuth, P., Hohn, K. G., Stenner, 
M. P., Budde, T., Wiendl, H., & Meuth, S. G. (2010) Upregulation of K2P5.1 potassium 
channels in multiple sclerosis. Ann.Neurol. 68: 58-69. 
Busija, D. W., Gaspar, T., Domoki, F., Katakam, P. V., & Bari, F. (2008) 
Mitochondrial-mediated suppression of ROS production upon exposure of neurons to 
lethal stress: mitochondrial targeted preconditioning. Adv.Drug Deliv.Rev. 60: 1471-
1477. 
Carrasco-Marin, E., Paz-Miguel, J. E., Lopez-Mato, P., Alvarez-Dominguez, C., & 
Leyva-Cobian, F. (1998) Oxidation of defined antigens allows protein unfolding and 
increases both proteolytic processing and exposes peptide epitopes which are 
recognized by specific T cells. Immunology 95: 314-321. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
24 
 
Carson, M. J., Doose, J. M., Melchior, B., Schmid, C. D., & Ploix, C. C. (2006) CNS 
immune privilege: hiding in plain sight. Immunol.Rev. 213: 48-65. 
Carson, M. J., Reilly, C. R., Sutcliffe, J. G., & Lo, D. (1998) Mature microglia resemble 
immature antigen-presenting cells. Glia 22: 72-85. 
Correia, S. C., Santos, R. X., Perry, G., Zhu, X., Moreira, P. I., & Smith, M. A. (2010) 
Mitochondria: the missing link between preconditioning and neuroprotection. 
J.Alzheimers.Dis. 20 Suppl 2: S475-S485. 
Freund, A., Orjalo, A. V., Desprez, P. Y., & Campisi, J. (2010) Inflammatory networks 
during cellular senescence: causes and consequences. Trends Mol.Med. 16: 238-246. 
Gallo, P. M. & Gallucci, S. (2013) The dendritic cell response to classic, emerging, and 
homeostatic danger signals. Implications for autoimmunity. Front Immunol. 4: 138. 
Ghanshani, S., Wulff, H., Miller, M. J., Rohm, H., Neben, A., Gutman, G. A., Cahalan, 
M. D., & Chandy, K. G. (2000) Up-regulation of the IKCa1 potassium channel during 
T-cell activation. Molecular mechanism and functional consequences. J.Biol.Chem. 
275: 37137-37149. 
Gocke, A. R., Lebson, L. A., Grishkan, I. V., Hu, L., Nguyen, H. M., Whartenby, K. A., 
Chandy, K. G., & Calabresi, P. A. (2012) Kv1.3 deletion biases T cells toward an 
immunoregulatory phenotype and renders mice resistant to autoimmune 
encephalomyelitis. J.Immunol. 188: 5877-5886. 
Goverman, J. (2009) Autoimmune T cell responses in the central nervous system. 
Nat.Rev.Immunol. 9: 393-407. 
Holmuhamedov, E., Lewis, L., Bienengraeber, M., Holmuhamedova, M., Jahangir, A., 
& Terzic, A. (2002) Suppression of human tumor cell proliferation through 
mitochondrial targeting. FASEB J. 16: 1010-1016. 
Huang, L., Li, W., Li, B., & Zou, F. (2006) Activation of ATP-sensitive K channels 
protects hippocampal CA1 neurons from hypoxia by suppressing p53 expression. 
Neurosci.Lett. 398: 34-38. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
25 
 
Ichinose, M., Yonemochi, H., Sato, T., & Saikawa, T. (2003) Diazoxide triggers 
cardioprotection against apoptosis induced by oxidative stress. Am.J.Physiol Heart 
Circ.Physiol 284: H2235-H2241. 
Judge, S. I. & Bever, C. T., Jr. (2006) Potassium channel blockers in multiple sclerosis: 
neuronal Kv channels and effects of symptomatic treatment. Pharmacol.Ther. 111: 224-
259. 
Judge, S. I. & Smith, P. J. (2009) Patents related to therapeutic activation of K(ATP) 
and K(2P) potassium channels for neuroprotection: ischemic/hypoxic/anoxic injury and 
general anesthetics. Expert.Opin.Ther.Pat 19: 433-460. 
Kuras, Z., Yun, Y. H., Chimote, A. A., Neumeier, L., & Conforti, L. (2012) KCa3.1 and 
TRPM7 channels at the uropod regulate migration of activated human T cells. 
PLoS.One. 7: e43859. 
Liu, X., Wu, J. Y., Zhou, F., Sun, X. L., Yao, H. H., Yang, Y., Ding, J. H., & Hu, G. 
(2006) The regulation of rotenone-induced inflammatory factor production by ATP-
sensitive potassium channel expressed in BV-2 cells. Neurosci.Lett. 394: 131-135. 
Mannhold, R. (2004) KATP channel openers: structure-activity relationships and 
therapeutic potential. Med.Res.Rev. 24: 213-266. 
Marshall, N. A., Vickers, M. A., & Barker, R. N. (2003) Regulatory T cells secreting 
IL-10 dominate the immune response to EBV latent membrane protein 1. J.Immunol. 
170: 6183-6189. 
Meuth, S. G., Kleinschnitz, C., & Wiendl, H. (2008) Recent clinical trials and future 
therapies. J.Neurol. 255 Suppl 6: 93-96. 
Miura, T. & Miki, T. (2003) ATP-sensitive K+ channel openers: old drugs with new 
clinical benefits for the heart. Curr.Vasc.Pharmacol. 1: 251-258. 
Moghtadaei, M., Habibey, R., Ajami, M., Soleimani, M., Ebrahimi, S. A., & Pazoki-
Toroudi, H. (2012) Skeletal muscle post-conditioning by diazoxide, anti-oxidative and 
anti-apoptotic mechanisms. Mol.Biol.Rep. 39: 11093-11103. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
26 
 
Mora, J. R., Cheng, G., Picarella, D., Briskin, M., Buchanan, N., & von Andrian, U. H. 
(2005) Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from 
skin- and gut-associated lymphoid tissues. J.Exp.Med. 201: 303-316. 
Nichols, C. G. (2006) KATP channels as molecular sensors of cellular metabolism. 
Nature 440: 470-476. 
O'Connor, R. A. & Anderton, S. M. (2008) Foxp3+ regulatory T cells in the control of 
experimental CNS autoimmune disease. J.Neuroimmunol. 193: 1-11. 
Olsen, M. L. & Sontheimer, H. (2008) Functional implications for Kir4.1 channels in 
glial biology: from K+ buffering to cell differentiation. J.Neurochem. 107: 589-601. 
Quintana, A., Kummerow, C., Junker, C., Becherer, U., & Hoth, M. (2009) 
Morphological changes of T cells following formation of the immunological synapse 
modulate intracellular calcium signals. Cell Calcium 45: 109-122. 
Rahn, E. J., Iannitti, T., Donahue, R.R., Taylor, B.K. (2014) Sex differences in a mouse 
model of multiple sclerosis: neuropathic pain behavior in females but not males and 
protection from neurological deficits during proestrus. Biol Sex Differ. 28;5(1):4.  
Rodriguez, M. J., Martinez-Moreno, M., Ortega, F. J., & Mahy, N. (2013) Targeting 
microglial K(ATP) channels to treat neurodegenerative diseases: a mitochondrial issue. 
Oxid.Med.Cell Longev. 2013: 194546. 
Shrikant, P. & Benveniste, E. N. (1996) The central nervous system as an 
immunocompetent organ: role of glial cells in antigen presentation. J.Immunol. 157: 
1819-1822. 
Skaper, S. D. (2011) Ion channels on microglia: therapeutic targets for neuroprotection. 
CNS.Neurol.Disord.Drug Targets. 10: 44-56. 
Steinhauser, C., Seifert, G., & Bedner, P. (2012) Astrocyte dysfunction in temporal lobe 
epilepsy: K+ channels and gap junction coupling. Glia 60: 1192-1202. 
Toldi, G., Folyovich, A., Simon, Z., Zsiga, K., Kaposi, A., Meszaros, G., Tulassay, T., 
& Vasarhelyi, B. (2011) Lymphocyte calcium influx kinetics in multiple sclerosis 
treated without or with interferon beta. J.Neuroimmunol. 237: 80-86. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
27 
 
Trapp, B. D. & Nave, K. A. (2008) Multiple sclerosis: an immune or neurodegenerative 
disorder? Annu.Rev.Neurosci. 31: 247-269. 
Tsunoda, I., Libbey, J. E., Kuang, L. Q., Terry, E. J., & Fujinami, R. S. (2005) Massive 
apoptosis in lymphoid organs in animal models for primary and secondary progressive 
multiple sclerosis. Am.J.Pathol. 167: 1631-1646. 
Virgili, N., Espinosa-Parrilla, J. F., Mancera, P., Pasten-Zamorano, A., Gimeno-Bayon, 
J., Rodriguez, M. J., Mahy, N., & Pugliese, M. (2011) Oral administration of the KATP 
channel opener diazoxide ameliorates disease progression in a murine model of multiple 
sclerosis. J.Neuroinflammation. 8: 149. 
Wang, H., Li, J., Follett, P. L., Zhang, Y., Cotanche, D. A., Jensen, F. E., Volpe, J. J., & 
Rosenberg, P. A. (2004) 12-Lipoxygenase plays a key role in cell death caused by 
glutathione depletion and arachidonic acid in rat oligodendrocytes. Eur.J.Neurosci. 20: 
2049-2058. 
Wang, J., Li, Z., Feng, M., Ren, K., Shen, G., Zhao, C., Jin, X., & Jiang, K. (2013) 
Opening of astrocytic mitochondrial ATP-sensitive potassium channels upregulates 
electrical coupling between hippocampal astrocytes in rat brain slices. PLoS.One. 8: 
e56605. 
Xie, J., Duan, L., Qian, X., Huang, X., Ding, J., & Hu, G. (2010) K(ATP) channel 
openers protect mesencephalic neurons against MPP+-induced cytotoxicity via 
inhibition of ROS production. J.Neurosci.Res. 88: 428-437. 
Yamada, K. & Inagaki, N. (2005) Neuroprotection by KATP channels. J.Mol.Cell 
Cardiol. 38: 945-949. 
Yasu, T., Ikeda, N., Ishizuka, N., Matsuda, E., Kawakami, M., Kuroki, M., Imai, N., 
Ueba, H., Fukuda, S., Schmid-Schonbein, G. W., & Saito, M. (2002) Nicorandil and 
leukocyte activation. J.Cardiovasc.Pharmacol. 40: 684-692. 
Zhou, F., Yao, H. H., Wu, J. Y., Ding, J. H., Sun, T., & Hu, G. (2008) Opening of 
microglial K(ATP) channels inhibits rotenone-induced neuroinflammation. J.Cell 
Mol.Med. 12: 1559-1570. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
28 
 
FIGURE LEGENDS 
Figure 1. Diazoxide ameliorates EAE course and decreases splenocyte proliferative 
capacity in the MOG35-55 EAE mice  
Oral 0.8 mg/Kg/day diazoxide treatment from the disease onset ameliorated EAE 
clinical course at some days of the experiment (n=14 mice/group) (A). Flow cytometry 
analysis  for CD4
+
 T cells in total splenocytes from diazoxide and vehicle treated EAE 
animals showed no differences in the percentage of positive events (n=12 mice/group) 
(B). T cell proliferation after splenocytic stimulation with anti-CD3 and anti-CD28 
antibodies for 72 hours showed a significant reduction in the proliferation rate of cells 
obtained from diazoxide treated animals when compared to vehicle treated EAE mice 
(C). Results showed as mean ± SEM.  *: p<0.05; **: p<0.01 compared to Vehicle group 
 
Figure 2. Diazoxide treatment of MOG35-55 EAE mice preserves spleen integrity  
Macroscopic images of non-immunized healthy mice (left), vehicle control EAE mice 
(center) and 0.8 mg/Kg/day diazoxide treated EAE mice (right) showed hypoplasia and 
signs of degeneration in control EAE but not in diazoxide treated EAE mice when 
compared to healthy animals (A). Upon splenocyte isolation, cell count demonstrated a 
significant increase of splenocytes in diazoxide treated EAE mice (n=12 mice/group) 
(B). Microscopic reconstruction of a spleen section stained with the H&E from control 
EAE mouse showed clear signs of necrosis (black arrows) and intercellular disruption 
(inferior square, higher magnification) whereas in the spleen from diazoxide treated 
EAE mouse, a normal tissue composition was observed (C). Scale bar for A: 5 mm. 
Scale bar for B: 1,5mm (for reconstruction) and 500 m (for magnification). **: p<0.01 
compared to Vehicle group. 
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Figure 3. KATP channel subunits are expressed in CD4
+
 CD3
+
 lymphocytes 
Double immunofluorescent staining demonstrated positive signal for Kir6.2 (green) and 
CD3 (red) staining in spleen CD4
+
 cells isolated with magnetic beads (A). Infiltrated T 
lymphocytes in the spinal cord white matter from EAE mice identified by CD3 positive 
signal (red) showed co-localization with Kir6.2 immunosignal (green, white arrows) 
(B). Western blot using protein from total splenocytes but also from spleen isolated 
CD4
+
 lymphocytes demonstrated positive expression for Kir6.1, Kir6.2 and SUR1 KATP 
channel subunits (C). Scale bar: 25 m for A and 100 m for B. 
 
Figure 4. Diazoxide does not modify lymphocytes activation in anti-CD3-CD28 T 
cell activation model 
Representative flow cytometry results on CD69 and CD25 expression. After 4 hours 
stimulation, splenocytes and CD4
+
 T cells increased CD69 expression. Treatment with 
diazoxide (100 and 0.1 M) did not change CD69 profile (A). The late activation 
marker, CD25, increased in splenocytes and CD4
+
 T cells after 16 hours of stimulation. 
Treatment with diazoxide (100 and 0.1 M) did not modify the expression of this 
marker (B). A minimum of three experiments were performed for each condition. 
 
Figure 5. Diazoxide modulates proliferation from splenocytes but not from CD4
+
 T 
cells 
Cell proliferation was determined by colorimetric BrdU incorporation assay. Ex vivo 
proliferation response of lymphocytes stimulated with anti-CD3-CD28 for 72 hours 
increased at least five fold times in splenocytes and CD4
+
T cells compared to 
unstimulated lymphocytes (Cell proliferation rate for unstimulated cells =1, Not 
stimulated bar). Pre-treatment with diazoxide showed a significant decrease at all dose 
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tested compared to anti-CD3-CD28 stimulated splenocytes (A). In contrast when the 
same experiments were performed with CD4
+
 T cell isolated cells diazoxide effect was 
abolished and there were no differences in proliferation rate compared to control (B). 
Results showed as mean ± SEM.  *: p<0.05; **: p<0.01 treated cells compared to 
untreated CD3-CD28 stimulated cells. n= 4-5 independent experiments.  
 
Figure 6. Diazoxide modulates dendritic cell development and maturation 
Flow cytometry analysis after diazoxide treatment during DCs development and 
maturation. Representative panels show CD83 analysis in DCs stimulated and 
unstimulated with LPS (A). Results showed that the decrease in CD83 surface 
expression in diazoxide treated cells was independent from LPS stimulation. This 
decrease was more pronounced for the lower dose tested (0.1 M) (B). Surface markers 
for maturation were also analyzed in DCs treated with LPS. Results showed that 
diazoxide treatment decrease the percentage of positive cells, compared to control. This 
decrease was significant for CD80 expression (C). Results showed as mean±SEM. *: 
p<0.05; **: p<0.01 compared to control DCs. n= 3-6 independent experiments.  
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